Mizuho reiterates uniQure stock rating, sees buying opportunity amid drop

uniQure BV (QURE) shares declined 10% on Monday and nearly 15% over the past week, driven by investor anticipation for 3-year AMT-130 Huntington’s disease data that was not released as expected. Mizuho maintained its Outperform rating and $30.00 price target, clarifying the data is still on track for late September and viewing the current weakness as a buying opportunity ahead of anticipated positive results. This comes as the company also reported positive initial Phase I/IIa data for its Fabry disease gene therapy, AMT-191, demonstrating significant enzyme activity and successful discontinuation of enzyme replacement therapy, which H.C. Wainwright cited in reiterating a $70 Buy rating.

Analysis

uniQure N.V. (QURE) has experienced significant share price volatility, declining nearly 15% over the past week and sharply underperforming the XBI biotech index. This sell-off appears to be technically driven by a misalignment of investor expectations regarding the timing of its 3-year Phase 1/2 data for AMT-130 in Huntington’s disease, which was not released as some had anticipated. Mizuho analysts clarify this data remains on track for a late September release, framing the current share price weakness as a buying opportunity based on their expectation of positive results. The company's underlying fundamentals present a mixed picture; second-quarter revenue of $5.3 million missed consensus and marked a steep decline from $11.1 million year-over-year due to drops in collaboration and manufacturing revenue. However, the reported loss per share of $0.69 was narrower than the anticipated $0.89 loss. Balancing this financial performance is a positive pipeline development in its Fabry disease program, where initial Phase I/IIa data for AMT-191 showed substantial increases in enzyme activity (27- to 208-fold) and enabled all patients to discontinue prior therapies. This clinical success prompted H.C. Wainwright to reiterate a Buy rating with a $70 price target, contrasting with Mizuho's $30 target, highlighting strong but varied analyst conviction based on different pipeline assets.

Key Decisions for Investors

• Investors may view the recent 15% share price decline, attributed to a data release timing misconception, as a high-risk entry point ahead of the pivotal 3-year AMT-130 Huntington's disease data catalyst expected in late September.
• Evaluate the investment case based on two distinct clinical assets: the near-term, high-impact Huntington's data release and the longer-term value proposition from the promising initial data in the AMT-191 Fabry disease program.
• Despite bullish analyst targets of $30 and $70, investors must weigh the company's clinical potential against fundamental weaknesses, specifically the significant Q2 revenue decline, which indicates ongoing commercial and collaboration challenges.